Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pelthos Therapeutics (PTHS) Other Non-Current Liabilities (2025)

Pelthos Therapeutics has reported Other Non-Current Liabilities over the past 1 years, most recently at $30.0 million for Q4 2025.

  • Quarterly results put Other Non-Current Liabilities at $30.0 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $30.0 million (changed N/A YoY), and the annual figure for FY2025 was $30.0 million, changed.
  • Other Non-Current Liabilities for Q4 2025 was $30.0 million at Pelthos Therapeutics, up from $26.2 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for PTHS hit a ceiling of $30.0 million in Q4 2025 and a floor of $26.2 million in Q3 2025.